Abstract
© 2016 The Authors. Published under the terms of the CC BY 4.0 license In a number of human cancers, NTN1 upregulation inhibits apoptosis induced by its so-called dependence receptors DCC and UNC5H, thus promoting tumor progression. In other cancers however, the selective inhibition of this dependence receptor death pathway relies on the silencing of pro-apoptotic effector proteins. We show here that a substantial fraction of human breast tumors exhibits simultaneous DNA methylation-dependent loss of expression of NTN1 and of DAPK1, a serine threonine kinase known to transduce the netrin-1 dependence receptor pro-apoptotic pathway. The inhibition of DNA methylation by drugs such as decitabine restores the expression of both NTN1 and DAPK1 in netrin-1-low cancer cells. Furthermore, a combination of decitabine with NTN1 silencing strategies or with an anti-netrin-1 neutralizing antibody potentiates tumor cell death and efficiently blocks tumor growth in different animal models. Thus, combining DNA methylation inhibitors with netrin-1 neutralizing agents may be a valuable strategy for combating cancer.
Cite
CITATION STYLE
Grandin, M., Mathot, P., Devailly, G., Bidet, Y., Ghantous, A., Favrot, C., … Dante, R. (2016). Inhibition of DNA methylation promotes breast tumor sensitivity to netrin‐1 interference. EMBO Molecular Medicine, 8(8), 863–877. https://doi.org/10.15252/emmm.201505945
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.